Avalyn Pharma Inc.

424B4 priced

Price $18.00 · 16,666,667 shares · Gross proceeds $300,000,006

Avalyn Pharma Inc. is conducting its initial public offering (IPO) of 16,666,667 shares of common stock at $18.00 per share, raising $300 million. The company, a clinical-stage biopharmaceutical firm, focuses on inhaled therapies for rare respiratory diseases like pulmonary fibrosis. Its pipeline includes AP01 and AP02, inhaled formulations of pirfenidone and nintedanib, which show favorable tolerability and preliminary clinical activity. The offering is underwritten by Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities, with shares listed on Nasdaq under 'AVLN'.

EFFECT effective

The filing represents a Notice of Effectiveness for Avalyn Pharma Inc.'s S-1 registration statement, indicating the SEC has accepted the filing for an upcoming IPO. The document includes standard SEC formatting and metadata but lacks readable content in the provided text.

CERT inactive

The current filing for Avalyn Pharma Inc. is a CERT form, following a previous S-1/A filing. The narrative summary is limited due to the lack of readable content in the current filing text, but it likely relates to the company's pre-IPO financial and operational details, similar to the S-1/A filing. No explicit changes or updates are discernible from the provided text.

S-1/A amended

Range $16.00 to $18.00 · 16,666,667 shares

Avalyn Pharma Inc. is conducting an IPO to raise capital for its clinical-stage inhaled therapies targeting rare respiratory diseases like pulmonary fibrosis. The offering includes 16,666,667 shares of common stock with an estimated price range of $16.00-$18.00. The company focuses on improving treatment efficacy and tolerability by delivering approved oral medications directly to the lungs. Avalyn is an emerging growth company with multiple drug candidates in Phase 1b, Phase 2b, and Phase 2 trials, including AP01 and AP02 for pulmonary fibrosis. The IPO is contingent on Nasdaq listing and includes underwriters Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities.

8-A12B effective

Avalyn Pharma Inc. is registering its common stock for listing on The Nasdaq Stock Market LLC, referencing the information from its previous S-1/A registration statement. The current 8-A12B filing focuses on the registration of securities under Section 12(b) of the Exchange Act, incorporating details from the earlier S-1 filing without additional substantive changes.

S-1/A amended

Range $16.00 to $18.00 · 11,800,000 shares

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for rare respiratory diseases, particularly pulmonary fibrosis. The company's pipeline includes AP01 and AP02, inhaled formulations of pirfenidone and nintedanib, respectively, targeting progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF). The S-1/A filing details an initial public offering (IPO) of 11,800,000 shares of common stock at an estimated price range of $16.00-$18.00 per share, with underwriters including Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities. The offering aims to fund clinical trials, research, and commercialization efforts, with the company positioning itself as an emerging growth company.

S-1 filed

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for rare respiratory diseases, particularly pulmonary fibrosis. The company's pipeline includes AP01 and AP02, inhaled formulations of pirfenidone and nintedanib, respectively, for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. AP03, a fixed-dose combination of both drugs, is advancing to Phase 1 trials. The IPO aims to fund clinical development and commercialization efforts, with shares expected to be listed on the Nasdaq Global Market under 'AVLN'. The company highlights potential advantages of inhaled therapies over oral treatments, including improved tolerability and efficacy.

DRS/A amended

Avalyn Pharma Inc. is conducting its initial public offering (IPO) of common stock, aiming to list on the Nasdaq Global Market under the symbol 'AVLN.' The company focuses on developing inhaled therapies for rare respiratory diseases, particularly pulmonary fibrosis, with clinical-stage candidates AP01 and AP02. The filing highlights the company's emerging growth status, reduced reporting requirements, and risks related to clinical trial outcomes, regulatory approvals, and market competition. The IPO proceeds will fund ongoing trials and commercialization efforts.

DRS filed

Avalyn Pharma Inc. is conducting an initial public offering (IPO) of its common stock, seeking to list on the Nasdaq Global Market under the symbol 'AVLN.' The company is a clinical-stage biopharmaceutical firm focused on developing inhaled therapies for rare respiratory diseases, including pulmonary fibrosis. Its pipeline includes AP01 and AP02, inhaled formulations of pirfenidone and nintedanib, which are in Phase 2 trials. Avalyn is an emerging growth company and smaller reporting company, with no prior public market for its stock. The offering includes underwriting discounts and a directed share program for insiders.